Atlas Venture Fund XI, L.P. - 08 Feb 2024 Form 4 Insider Report for Xilio Therapeutics, Inc. (XLO)

Role
10%+ Owner
Signature
Atlas Venture Fund XI, L.P. By: Atlas Venture Associates XI, L.P., Its: General Partner By: Atlas Venture Associates XI, LLC, Its General Partner, By: Ommer Chohan, Chief Financial Officer, /s/ Ommer Chohan
Issuer symbol
XLO
Transactions as of
08 Feb 2024
Transactions value $
-$640
Form type
4
Filing time
09 Feb 2024, 16:33:08 UTC
Previous filing
16 Jan 2024
Next filing
20 Feb 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction XLO Common Stock Sale -$469 -733 -0.04% $0.64 2.02M 08 Feb 2024 Direct F1
transaction XLO Common Stock Sale -$171 -267 -0.04% $0.64 735K 08 Feb 2024 See footnote F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Atlas Venture Fund XI, L.P. is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 The shares are held directly by Atlas Venture Fund XI, L.P. ("Atlas Venture Fund XI"). The general partner of Atlas Venture Fund XI is Atlas Venture Associates XI, L.P. ("AVA XI LP"). Atlas Venture Associates XI, LLC ("AVA XI LLC") is the general partner of AVA XI LP. Each of AVA XI LP and AVA XI LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Fund XI, except to the extent of its pecuniary interest therein, if any.
F2 The shares are held directly by Atlas Venture Opportunity Fund I, L.P. ("Atlas Venture Opportunity Fund I"). The general partner of Atlas Venture Opportunity Fund I is Atlas Venture Associates Opportunity I, L.P. ("AVAO I LP"). Atlas Venture Associates Opportunity I, LLC ("AVAO I LLC") is the general partner of AVAO I LP. Each of AVAO I LP and AVAO I LLC disclaims Section 16 beneficial ownership of the securities held by Atlas Venture Opportunity Fund I, except to the extent of its pecuniary interest therein, if any.